CNS Clinical Trials, Therapeutics & Clinical Guidelines

Clinical validation indicates that the plasma p-tau217 assay achieves diagnostic accuracy comparable to Amyloid-PET and CSF analysis in primary care settings, providing an accessible biomarker for early Alzheimer’s disease detection.

Preclinical and early Phase 1 data indicate that stimulating the TREM2 receptor activates microglial clearance of amyloid-beta plaques and preserves synaptic plasticity, supporting TREM2 agonism as an immunotherapeutic strategy for Alzheimer's disease.

Analysis of over 10,000 cases suggests that APOE4 homozygosity behaves as a distinct, genetically determined form of Alzheimer's disease with near-complete amyloid penetrance, rather than solely a risk factor.

Examines combination therapy strategies that pair anti-amyloid monoclonal antibodies with tau-targeted (MTBR-tau) antibodies to address secondary neurodegeneration following initial plaque clearance.

Demonstrates that combining serum GFAP (astrocytic smoldering progression) with serum NfL (acute axonal injury) and retinal OCT accurately predicts 24-week confirmed Progression Independent of Relapse Activity (PIRA) in Multiple Sclerosis.

Phase 3 clinical trial results demonstrate that the CNS-penetrant BTK inhibitor tolebrutinib slows 6-month confirmed disability accumulation in non-relapsing secondary progressive MS by modulating microglial neuroinflammation and B-cell signaling behind the blood-brain barrier.